Home Economy News Novo Nordisk’s Wegovy gains FDA approval for cardiovascular benefits

Novo Nordisk’s Wegovy gains FDA approval for cardiovascular benefits


Novo Nordisk’s Wegovy gains FDA approval for cardiovascular benefits By Investing.com

Breaking News


EditorBrando BricchiEconomy

Published Mar 08, 2024 02:05PM ET

Novo Nordisk (NYSE:NVO) disclosed today that the US Food and Drug Administration (FDA) has sanctioned an expanded use for its drug Wegovy®. This approval allows the medication to be marketed for reducing the likelihood of major adverse cardiovascular events (MACE), which include cardiovascular death, non-fatal heart attacks, or non-fatal strokes. This indication is specifically for adults who are overweight or obese and have pre-existing cardiovascular disease (CVD).

The FDA’s decision is rooted in the results of the SELECT cardiovascular outcomes trial. Data from this study revealed that Wegovy® could significantly decrease the risk of MACE by 20% compared to a placebo, in conjunction with standard care. The trial also highlighted that the benefits of Wegovy® were consistent across various subgroups, including different ages, genders, races, ethnicities, body mass indices (BMIs), and levels of renal function impairment.

Furthermore, the updated drug label now includes SELECT trial data indicating a 15% reduction in cardiovascular death and a 19% reduction in death from any cause, both in comparison to placebo. These figures underscore the potential impact of the drug on patient longevity.

Martin Holst Lange, executive vice president and head of Development at Novo Nordisk, expressed the company’s satisfaction with the FDA’s approval, emphasizing the significance of Wegovy® as the first therapy of its kind to help individuals manage weight and mitigate cardiovascular risks. The company anticipates that this approval will be a crucial development for patients living with obesity and cardiovascular disease.

In addition to the FDA approval, Novo Nordisk has submitted a request for label expansion in the European Union, with an expected decision in 2024. This news is based on a press release statement and reflects the company’s ongoing commitment to addressing significant health challenges associated with obesity and cardiovascular disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Novo Nordisk’s Wegovy gains FDA approval for cardiovascular benefits

Our Apps

Terms And Conditions
Privacy Policy
Risk Warning
Do not sell my personal information

© 2007-2024 Fusion Media Limited. All Rights Reserved.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Related News